Cargando…
Co-designing a community pharmacy pharmacogenomics testing service in the UK
INTRODUCTION: Pharmacogenomics (PGx) testing services have been delivered through community pharmacies across the globe, though not yet in the UK. This paper is reporting a focus group study, the first stage of a participatory co-design process to increase the chance of a successful implementation o...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939480/ https://www.ncbi.nlm.nih.gov/pubmed/35317803 http://dx.doi.org/10.1186/s12913-022-07730-y |
_version_ | 1784672735418384384 |
---|---|
author | Rendell, Tim Barnett, Julie Wright, David |
author_facet | Rendell, Tim Barnett, Julie Wright, David |
author_sort | Rendell, Tim |
collection | PubMed |
description | INTRODUCTION: Pharmacogenomics (PGx) testing services have been delivered through community pharmacies across the globe, though not yet in the UK. This paper is reporting a focus group study, the first stage of a participatory co-design process to increase the chance of a successful implementation of a PGx service through community pharmacy in the UK. AIM: To identify the barriers and enablers to implementing a community pharmacy based PGx service in the UK. METHOD: Three focus groups were conducted with community pharmacists (n = 10), prescribers (n = 8) and patients (n = 8) in England. The focus groups were recorded, transcribed and thematically analysed using the Braun and Clarke six phase reflexive thematic analysis approach. RESULTS: The analysis identified five themes about PGx testing in community pharmacies: (1) In- principle receptiveness, (2) Appreciation of the benefits, (3) Lack of implementation resources (4) Ambiguity about implications for implementation and (5) Interprofessional relationship challenges. CONCLUSION: The identified enablers for implementation of a PGx service were at a macro health system strategic level; the concerns were more at a granular operational procedural level. Overall receptiveness was noted by all three participant groups, and both prescriber and pharmacist groups appreciated the potential benefits for patients and the healthcare system. Prior to implementation in the UK, there is a need to disambiguate health professional’s concerns of the guidance, resources, and knowledge required to set up and deliver the service and to resolve patient concerns about the nature of genomics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-022-07730-y. |
format | Online Article Text |
id | pubmed-8939480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89394802022-03-23 Co-designing a community pharmacy pharmacogenomics testing service in the UK Rendell, Tim Barnett, Julie Wright, David BMC Health Serv Res Research INTRODUCTION: Pharmacogenomics (PGx) testing services have been delivered through community pharmacies across the globe, though not yet in the UK. This paper is reporting a focus group study, the first stage of a participatory co-design process to increase the chance of a successful implementation of a PGx service through community pharmacy in the UK. AIM: To identify the barriers and enablers to implementing a community pharmacy based PGx service in the UK. METHOD: Three focus groups were conducted with community pharmacists (n = 10), prescribers (n = 8) and patients (n = 8) in England. The focus groups were recorded, transcribed and thematically analysed using the Braun and Clarke six phase reflexive thematic analysis approach. RESULTS: The analysis identified five themes about PGx testing in community pharmacies: (1) In- principle receptiveness, (2) Appreciation of the benefits, (3) Lack of implementation resources (4) Ambiguity about implications for implementation and (5) Interprofessional relationship challenges. CONCLUSION: The identified enablers for implementation of a PGx service were at a macro health system strategic level; the concerns were more at a granular operational procedural level. Overall receptiveness was noted by all three participant groups, and both prescriber and pharmacist groups appreciated the potential benefits for patients and the healthcare system. Prior to implementation in the UK, there is a need to disambiguate health professional’s concerns of the guidance, resources, and knowledge required to set up and deliver the service and to resolve patient concerns about the nature of genomics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-022-07730-y. BioMed Central 2022-03-22 /pmc/articles/PMC8939480/ /pubmed/35317803 http://dx.doi.org/10.1186/s12913-022-07730-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rendell, Tim Barnett, Julie Wright, David Co-designing a community pharmacy pharmacogenomics testing service in the UK |
title | Co-designing a community pharmacy pharmacogenomics testing service in the UK |
title_full | Co-designing a community pharmacy pharmacogenomics testing service in the UK |
title_fullStr | Co-designing a community pharmacy pharmacogenomics testing service in the UK |
title_full_unstemmed | Co-designing a community pharmacy pharmacogenomics testing service in the UK |
title_short | Co-designing a community pharmacy pharmacogenomics testing service in the UK |
title_sort | co-designing a community pharmacy pharmacogenomics testing service in the uk |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939480/ https://www.ncbi.nlm.nih.gov/pubmed/35317803 http://dx.doi.org/10.1186/s12913-022-07730-y |
work_keys_str_mv | AT rendelltim codesigningacommunitypharmacypharmacogenomicstestingserviceintheuk AT barnettjulie codesigningacommunitypharmacypharmacogenomicstestingserviceintheuk AT wrightdavid codesigningacommunitypharmacypharmacogenomicstestingserviceintheuk |